Long-Term Efficacy of Immune Checkpoint Inhibitor for Squamous Cell Carcinoma Lesion Transformed From EGFR-Mutated Adenocarcinoma After Osimertinib Treatment: A Case Report

• الحاوية / القاعدة: JTO Clinical and Research Reports
• المؤلفون الرئيسيون: Shota Takahashi, MD, Yuki Sato, MD, Yoshiharu Sato, PhD, Ryosuke Hirabayashi, MD, Shigeo Hara, MD, PhD, Yutaka Takahashi, MD, PhD, Keisuke Tomii, MD, PhD
• التنسيق: مقال
• اللغة: الإنجليزية
• منشور في: Elsevier 2024-02-01
• الموضوعات: Acquired resistance; Histologic transformation; Osimertinib; Immune checkpoint inhibitor; Case report
• الوصول للمادة أونلاين: http://www.sciencedirect.com/science/article/pii/S2666364324000092

Histologic transformation is one of the mechanisms of resistance to EGFR tyrosine kinase inhibitor in patients with NSCLC with EGFR mutation. The transformation from adenocarcinoma to squamous cell carcinoma (SCC) has been recently recognized as a mechanism of resistance to osimertinib. The prognosis after transformation to SCC is considered to be poor, and the therapeutic strategy for these patients is unclear. Herein, we report a case of long-term response to pembrolizumab monotherapy for an SCC-transformed lesion in a patient with EGFR-mutated adenocarcinoma after osimertinib treatment. A 68-year-old man underwent right upper lobectomy and was diagnosed with lung adenocarcinoma, pathologic stage IIA, with EGFR L858R. Five years after the surgery, he was diagnosed with recurrence and administered osimertinib. Ten months after, biopsy for an enlarged subpleural lesion revealed SCC with EGFR L858R, leading to a diagnosis of histologic transformation. Notably, the programmed death-ligand 1 expression level of the transformed lesion was higher than that of the adenocarcinoma (90% versus <1%). The size of the SCC lesion had reduced with pembrolizumab monotherapy, and the reduction was maintained for over 47 months since transformation. Nevertheless, the original adenocarcinoma lesion progressed after pembrolizumab therapy and was controlled by other cytotoxic drugs and readministration of osimertinib. Immune checkpoint inhibitor therapy is generally ineffective against EGFR-mutated adenocarcinoma. Nevertheless, it may be promising for achieving a good prognosis when EGFR-mutated adenocarcinoma transforms to SCC after developing EGFR tyrosine kinase inhibitor resistance—particularly if the transformed lesion has high programmed death-ligand 1 expression.